{
    "clinical_study": {
        "@rank": "156536", 
        "arm_group": [
            {
                "arm_group_label": "Etafilcon A Control Lens", 
                "arm_group_type": "Active Comparator", 
                "description": "etafilcon A"
            }, 
            {
                "arm_group_label": "Etafilcon A Test Lens", 
                "arm_group_type": "Experimental", 
                "description": "etafilcon A"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the clinical performance of daily disposable etafilcon \"A lenses."
        }, 
        "brief_title": "Evaluation of Etafilcon A Daily Disposable Lenses", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Myopia", 
        "condition_browse": {
            "mesh_term": "Myopia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and\n             receive a fully executed copy of the form.\n\n          -  The subject must appear able and willing to adhere to the instructions set forth in\n             this clinical protocol.\n\n          -  The subject must be at least 18 and not more than 70 years of age.\n\n          -  The subject's refractive cylinder must be < 1.00D in each eye.\n\n          -  The subject must have best corrected visual acuity of 20/25 or better in each eye.\n\n          -  The subject's required spherical contact lens prescription must be in the range of\n             -0.50 to -7.50D in each eye.\n\n          -  The subject must be a habitual and adapted wearer of daily disposable contact lens in\n             both eyes.\n\n          -  The subject must self-report their race as Asian\n\n          -  The subject must have normal eyes (i.e., no ocular medications or infections of any\n             type).\n\n          -  The subject must demonstrate adequate mobility and 20/30 vision OD and OS with the\n             study contact lenses.\n\n        Exclusion Criteria:\n\n          -  Currently pregnant or lactating (subjects who become pregnant during the study will\n             be discontinued).\n\n          -  Any ocular or systemic allergies or diseases that may interfere with contact lens\n             wear.\n\n          -  Any systemic disease, autoimmune disease, or use of medication that may interfere\n             with contact lens wear.\n\n          -  Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of\n             recurrent corneal erosions, aphakia.\n\n          -  Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy,\n             PRK, LASIK, etc.).\n\n          -  Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization,\n             corneal staining, tarsal abnormalities, conjunctival injection) on the FDA\n             classification scale, any previous history or signs of a contact lens-related corneal\n             inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any\n             other ocular abnormality that may contraindicate contact lens wear.\n\n          -  Any ocular infection.\n\n          -  Any corneal distortion resulting from previous hard or rigid gas permeable contact\n             lens wear.\n\n          -  Monovision or multi-focal contact lens correction.\n\n          -  Participation in any contact lens or lens care product clinical trial within 14 days\n             prior to study enrollment.\n\n          -  History of binocular vision abnormality or strabismus.\n\n          -  Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious\n             immunosuppressive disease (e.g., HIV, by self report).\n\n          -  Suspicion of or recent history of alcohol or substance abuse.\n\n          -  History of serious mental illness.\n\n          -  History of seizures.\n\n          -  Employee of investigational clinic (e.g., Investigator, Coordinator, Technician)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "136", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061592", 
            "org_study_id": "CR-5553"
        }, 
        "intervention": [
            {
                "arm_group_label": "Etafilcon A Control Lens", 
                "intervention_name": "etafilcon A", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Etafilcon A Test Lens", 
                "intervention_name": "etafilcon A", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aiea", 
                        "country": "United States", 
                        "state": "Hawaii"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kahalui", 
                        "country": "United States", 
                        "state": "Hawaii"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waipahu", 
                        "country": "United States", 
                        "state": "Hawaii"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Evaluation of Two Etafilcon A Daily Disposable Lenses", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The primary endpoints in this study were subjective assessment of comfort and quality vision at 1-week follow-up.   Subjective assessment of comfort and overall quality of vision were performed using the Contact Lens User ExperienceTM (CLUE) questionnaire. CLUE was a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicated a more favorable/positive response with a range of 0 to 120.", 
                "measure": "Overall Comfort & Vision", 
                "safety_issue": "No", 
                "time_frame": "1-week follow-up"
            }, 
            {
                "description": "logMar visual acuity with each lens will be determined using ETDRS visual acuity charts.", 
                "measure": "logMAR Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "1-week follow-up"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Vistakon", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vistakon", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}